Barrow, Hanley, Mewhinney & Strauss, LLC 13F holdings and portfolio analysis
Sign in to clone a new branch from the selected plan, then continue optimizing in the new branch.
Baseline
Analysis messagesPre-generated Q&A about this fund. Use as reference context for your own analysis.
The latest change list shows MRK unchanged to 3.88%; CVX unchanged to 3.56%; GEHC unchanged to 3.45%. Combined with top 5 17.07%, top 10 30.88%, top 20 52.69%, that tells the user whether the baseline is becoming more concentrated or simply refreshing existing exposure. For a static page, this is the best first check before deciding whether the raw disclosed book is still acceptable.
Concentration is the first item to inspect: top 5 17.07%, top 10 30.88%, top 20 52.69%. The largest names are MRK (Merck & Co., Inc.) 3.88%, CVX (Chevron Corporation) 3.56%, GEHC (GE HealthCare Technologies Inc.) 3.45%, CCL (Carnival Corporation & plc) 3.12%, and ETR (Entergy Corporation) 3.06%, and the largest sector exposures are Financials 14.80%, Information Technology 14.29%, and Health Care 12.20%. If those exposures reverse, baseline performance can diverge sharply from a broad index.
The strongest recent period was 2025-09-30 (11.08% strategy return, 1.46% benchmark, 9.62% excess, 21.03% turnover), while the weakest was 2025-12-31 (3.18% strategy return, 9.57% benchmark, -6.39% excess, 26.39% turnover). Those periods should be read alongside baseline metrics of return 9.49%, alpha -0.67%, beta 0.75, Sharpe 0.68, Sortino 0.84, and max drawdown -33.39% to judge whether returns came from persistent exposure or a narrow timing window.